190 related articles for article (PubMed ID: 9639524)
21. Sézary T-cell activating factor is a Chlamydia pneumoniae-associated protein.
Abrams JT; Vonderheid EC; Kolbe S; Appelt DM; Arking EJ; Balin BJ
Clin Diagn Lab Immunol; 1999 Nov; 6(6):895-905. PubMed ID: 10548583
[TBL] [Abstract][Full Text] [Related]
22. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
23. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
24. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
[TBL] [Abstract][Full Text] [Related]
25. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
[TBL] [Abstract][Full Text] [Related]
26. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
27. Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides.
Haynes BF; Bunn P; Mann D; Thomas C; Eisenbarth GS; Minna J; Fauci AS
J Clin Invest; 1981 Feb; 67(2):523-30. PubMed ID: 6970206
[TBL] [Abstract][Full Text] [Related]
28. Serological detection of cutaneous T-cell lymphoma-associated antigens.
Eichmuller S; Usener D; Dummer R; Stein A; Thiel D; Schadendorf D
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):629-34. PubMed ID: 11149944
[TBL] [Abstract][Full Text] [Related]
29. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma.
Vowels BR; Lessin SR; Cassin M; Jaworsky C; Benoit B; Wolfe JT; Rook AH
J Invest Dermatol; 1994 Nov; 103(5):669-73. PubMed ID: 7963654
[TBL] [Abstract][Full Text] [Related]
30. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
31. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous T-cell lymphoma: a review.
Winkler CF; Bunn PA
Crit Rev Oncol Hematol; 1983; 1(1):49-92. PubMed ID: 6083835
[TBL] [Abstract][Full Text] [Related]
33. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
[TBL] [Abstract][Full Text] [Related]
34. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
35. [Interleukin 7 in dermatology. Molecular, immunologic and preclinical aspects].
Möller P; Czarnetzki BM; Schadendorf D
Hautarzt; 1995 Oct; 46(10):676-82. PubMed ID: 7499126
[TBL] [Abstract][Full Text] [Related]
36. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma.
Bagot M; Echchakir H; Mami-Chouaib F; Delfau-Larue MH; Charue D; Bernheim A; Chouaib S; Boumsell L; Bensussan A
Blood; 1998 Jun; 91(11):4331-41. PubMed ID: 9596682
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-7 is a growth factor for Sézary lymphoma cells.
Dalloul A; Laroche L; Bagot M; Mossalayi MD; Fourcade C; Thacker DJ; Hogge DE; Merle-Béral H; Debré P; Schmitt C
J Clin Invest; 1992 Sep; 90(3):1054-60. PubMed ID: 1381718
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
39. Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells.
Fox FE; Kubin M; Cassin M; Niu Z; Trinchieri G; Cooper KD; Rook AH
J Interferon Cytokine Res; 1999 Apr; 19(4):407-15. PubMed ID: 10334392
[TBL] [Abstract][Full Text] [Related]
40. Fulminant cutaneous T-cell lymphoma and Sézary syndrome.
Lang R; Bernheim J; Bar-Sela S; Joseph D; Ravid M
Int J Dermatol; 1986; 25(1):38-43. PubMed ID: 3485082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
